Achillion Initiates Phase 2 Interferon-Free Trial of Sovaprevir and ACH-3102 for Genotype 1 HCV

[at noodls] – NEW HAVEN, Conn., April 16, 2013 (GLOBE NEWSWIRE) — Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today announced that it has initiated an international Phase 2 clinical trial with sovaprevir and ACH-3102 … more

View todays social media effects on ACHN

View the latest stocks trending across Twitter. Click to view dashboard

See who Achillion is hiring next, click here to view